UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration

Molecular pharmaceutics, 2019-05, Vol.16 (5), p.1958-1970

2019

Volltextzugriff (PDF)

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme

Clinical drug investigation, 2008-01, Vol.28 (10), p.625-634

2008

Volltextzugriff (PDF)

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Journal of clinical lipidology, 2018-01, Vol.12 (1), p.173-184

2018

Volltextzugriff (PDF)

A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate

European journal of pharmacology, 2023-01, Vol.938, p.175428-175428, Article 175428

2023

Volltextzugriff (PDF)

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form

Molecular pharmaceutics, 2021-09, Vol.18 (9), p.3588-3600

2021

Volltextzugriff (PDF)

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Expert opinion on pharmacotherapy, 2014-03, Vol.15 (4), p.493-503

2014

Volltextzugriff (PDF)

A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation

British journal of pharmacology, 2022-03, Vol.179 (6), p.1237-1250

2022

Volltextzugriff (PDF)

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Clinical pharmacology and therapeutics, 2020-12, Vol.108 (6), p.1213-1223

2020

Volltextzugriff (PDF)

Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits

Pharmacological research, 2019-06, Vol.144, p.132-141

2019

Volltextzugriff (PDF)

Fenofibrate inhibits MOXD1 and PDZK1IP1 expression and improves lipid deposition and inflammation in mice with alcoholic fatty liver

Life sciences (1973), 2024-01, Vol.336, p.122321-122321, Article 122321

2024

Volltextzugriff (PDF)

Efficacy and safety of fenofibrate in combination with phototherapy for the treatment of neonatal hyperbilirubinemia: a systematic review and meta-analyses

Canadian journal of physiology and pharmacology, 2024-04, Vol.102 (4), p.242

2024

Volltextzugriff (PDF)

Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway

Naunyn-Schmiedeberg's archives of pharmacology, 2024-02, Vol.397 (2), p.1025-1035

2024

Volltextzugriff (PDF)

Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials

Pharmacological research, 2015-12, Vol.102, p.63-70

2015

Volltextzugriff (PDF)

The PPARα agonist fenofibrate reduces the cytokine imbalance in a maternal immune activation model of schizophrenia

European journal of pharmacology, 2023-12, Vol.961, p.176172-176172, Article 176172

2023

Volltextzugriff (PDF)

Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease

Molecular pharmaceutics, 2023-01, Vol.20 (1), p.159-171

2023

Volltextzugriff (PDF)

Fenofibrate: A Review of its Use in Dyslipidaemia

Drugs (New York, N.Y.), 2011-10, Vol.71 (14), p.1917-1946

2011

Volltextzugriff (PDF)

Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease

Expert opinion on pharmacotherapy, 2019-11, Vol.20 (16), p.2007-2017

2019

Volltextzugriff (PDF)

Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway

European review for medical and pharmacological sciences, 2022-10, Vol.26 (20), p.7359

2022

Volltextzugriff (PDF)

Fenofibrate and Dyslipidemia: Still a Place in Therapy?

Drugs (New York, N.Y.), 2018-09, Vol.78 (13), p.1289-1296

2018

Volltextzugriff (PDF)

PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease

Progress in neuro-psychopharmacology & biological psychiatry, 2014-08, Vol.53, p.35-44

2014

Volltextzugriff (PDF)

Assessment of hypolipidemic, anti-inflammatory and antioxidant properties of medicinal plant Erica multiflora in triton WR-1339-induced hyperlipidemia and liver function repair in rats: A comparison with fenofibrate

Regulatory toxicology and pharmacology, 2019-10, Vol.107, p.104404, Article 104404

2019

Volltextzugriff (PDF)

The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia

Clinical and experimental pharmacology & physiology, 2021-02, Vol.48 (2), p.186-194

2021

Volltextzugriff (PDF)

Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats

Journal of pharmacological sciences, 2015-03, Vol.127 (3), p.244-250

2015

Volltextzugriff (PDF)

Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats

Naunyn-Schmiedeberg's archives of pharmacology, 2018-03, Vol.391 (3), p.309-321

2018

Volltextzugriff (PDF)

Fenofibrate Induces a Resolving Profile in Heart Macrophage Subsets and Attenuates Acute Chagas Myocarditis

ACS infectious diseases, 2024-05, Vol.10 (5), p.1793-1807

2024

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology & Pharmacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(170)

Publikationsform

Artikel
(222)

Sprache

Englisch
(220)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(222)
Science & Technology
(222)
Fenofibrate - Therapeutic Use
(191)
Humans
(175)
Hypolipidemic Agents - Therapeutic Use
(141)
Male
(140)
Fenofibrate
(132)
Female
(98)
Middle Aged
(93)
Biological And Medical Sciences
(76)
Medical Sciences
(75)
Animals
(70)
Fenofibrate - Pharmacology
(70)
Pharmacology. Drug Treatments
(67)
Adult
(58)
Triglycerides - Blood
(56)
Fenofibrate - Adverse Effects
(53)
Aged
(50)
Dyslipidemias - Drug Therapy
(49)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits

Fenofibrate inhibits MOXD1 and PDZK1IP1 expression and improves lipid deposition and inflammation in mice with alcoholic fatty liver

Efficacy and safety of fenofibrate in combination with phototherapy for the treatment of neonatal hyperbilirubinemia: a systematic review and meta-analyses

Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway

Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials

The PPARα agonist fenofibrate reduces the cytokine imbalance in a maternal immune activation model of schizophrenia

Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease

Fenofibrate: A Review of its Use in Dyslipidaemia

Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease

Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway

Fenofibrate and Dyslipidemia: Still a Place in Therapy?

PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease

Assessment of hypolipidemic, anti-inflammatory and antioxidant properties of medicinal plant Erica multiflora in triton WR-1339-induced hyperlipidemia and liver function repair in rats: A comparison with fenofibrate

The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia

Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats

Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats

Fenofibrate Induces a Resolving Profile in Heart Macrophage Subsets and Attenuates Acute Chagas Myocarditis

Aktive Filter

Suchergebnisse filtern